WO2007079558B1 - Proline-rich peptides, pharmaceutical composition, use of one or more peptides and method of treatment - Google Patents
Proline-rich peptides, pharmaceutical composition, use of one or more peptides and method of treatmentInfo
- Publication number
- WO2007079558B1 WO2007079558B1 PCT/BR2007/000003 BR2007000003W WO2007079558B1 WO 2007079558 B1 WO2007079558 B1 WO 2007079558B1 BR 2007000003 W BR2007000003 W BR 2007000003W WO 2007079558 B1 WO2007079558 B1 WO 2007079558B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- accordance
- treatment
- seq
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides oligopeptides with amino acid sequences comprised in set forth in SEQ ID NO 1 to 18, capable of binding to diverse targets, generating increase and sustenance to nitric oxide (NO) production in mammalian cells, potentiate the argininosuccinate synthase activity of animal cells and/or increase the intracellular bivalent calcium ion in animal cells. Also disclosed are pharmaceutical compositions of one or more peptides described in the present invention. The invention further relates to the use of these peptides.
Claims
AMENDED CLAIMS received by the International Bureau on 20 Augst 2007 (20.08.07) - Use of one or more of peptides SEQ ID NOS 1 to 18 in the manufacture of a pharmaceutical composition for the treatment or prevention of a disease caused by deficiency in nitric oxide production. - Pharmaceutical composition, in accordance with claim 1, characterized by comprising from 0.05 μg to 10 mg of one amino acid sequence set forth in SEQ ID NO 1 to 18 or a mixture thereof or pharmaceutically acceptable salts thereof. - Pharmaceutical composition, in accordance with claim 1, characterized by comprising from 0.5 μg to 5 mg of one amino acid sequence set forth in SEQ ID NO 1 to 18 or a mixture thereof or pharmaceutically acceptable salts thereof. - Pharmaceutical composition, in accordance with claim 1, characterized by comprising from 0.1 μg to 0.01 mg of one amino acid sequence set forth in SEQ ID NO 1 to 18 or a mixture thereof or pharmaceutically acceptable salts thereof. - Use of the pharmaceutical composition in accordance with the claims 1-4 for the treatment of cardiovascular diseases . - Use of the pharmaceutical composition in accordance with the claims 1-4 for the treatment of disorders of the nervous system. - Use of the pharmaceutical composition in accordance with the claims 1-4 for the treatment of disorders of the gastrointestinal system. - Use of the pharmaceutical composition in accordance with the claims 1-4 for the treatment of disorders of the immune system.
- Use of the pharmaceutical composition in accordance with the claims 1-4 for the treatment of disorders of the systemic, renal and coronary hemodynamics. 0- Use of the pharmaceutical composition in accordance with the claims 1-4 for the treatment of neurodegenerative pathologies. 1- Use of the pharmaceutical composition in accordance with the claims 1-4 for the treatment of pre-eclampsia. 2- Use of the pharmaceutical composition in accordance with the claims 1-4 for the treatment of lymphocyte dysfunction in the immune response and/or tumor growth. 3- Use of the pharmaceutical composition in accordance with the claims 1-4 for the treatment of erectile dysfunction. 4- Use of the pharmaceutical composition in accordance with the claims 1-4 to control the production of male germinative cells. 5- An oligopeptide characterized by comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 6-11, 17 and 18, having at least one activity of substantially enhancing and sustaining nitric oxide production in animal cells, potentiating argininosuccinate synthase activity of animal cells, and increasing the intracellular concentration of bivalent calcium ion in animal cells. 6- Method of regulating blood flow in animals, in accordance with claims 1-4, characterized by relaxation of artery smooth muscles by stimulating the endotethelial cells to produce nitric oxide by administering the pharmaceutical composition described in claims 2-4.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07700096A EP1979373A2 (en) | 2006-01-09 | 2007-01-05 | Proline-rich peptides, pharmaceutical composition, use of one or more peptides and method of treatment |
| JP2008548908A JP2009522314A (en) | 2006-01-09 | 2007-01-05 | Proline-rich peptides, pharmaceutical compositions, uses of one or more peptides and methods of treatment |
| US11/813,346 US20100035822A1 (en) | 2006-01-09 | 2007-01-05 | Proline-rich peptides, pharmaceutical composition, use of one or more peptides and method of treatment |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0600331 | 2006-01-09 | ||
| BRPI0600331-1 | 2006-01-09 | ||
| BRPI0607366-2 | 2006-12-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2007079558A2 WO2007079558A2 (en) | 2007-07-19 |
| WO2007079558A3 WO2007079558A3 (en) | 2007-08-30 |
| WO2007079558B1 true WO2007079558B1 (en) | 2007-10-04 |
Family
ID=38256648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR2007/000003 WO2007079558A2 (en) | 2006-01-09 | 2007-01-05 | Proline-rich peptides, pharmaceutical composition, use of one or more peptides and method of treatment |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007079558A2 (en) |
-
2007
- 2007-01-05 WO PCT/BR2007/000003 patent/WO2007079558A2/en active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007079558A3 (en) | 2007-08-30 |
| WO2007079558A2 (en) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8318805B2 (en) | Modulation of nitric oxide synthases by betaines | |
| Burnstock | Purinergic P2 receptors as targets for novel analgesics | |
| ES2661850T3 (en) | Toll type receiver modulators | |
| US20110293587A1 (en) | Glucagon analogues | |
| US20080275120A1 (en) | Leucine rich composition | |
| US20100158905A1 (en) | Combination therapy of arthritis with tranilast | |
| KR20200106173A (en) | Improved peptide drugs for the treatment of NASH and other diseases | |
| WO2011107653A8 (en) | Use of levodopa, carbidopa and entacapone for treating parkinson's disease | |
| US20200392197A1 (en) | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | |
| CN107531752A (en) | Treated for the peptide of inflammation and fibrosis | |
| JP2006506942A5 (en) | ||
| CA2427551A1 (en) | Use of stimulators of soluble guanylate cyclase for treating osteoporosis | |
| WO2003055481A1 (en) | Organ fibrosis inhibitors | |
| RU2582962C1 (en) | Agent for preventing and treating neurodegenerative pathology and vascular dementia (versions) | |
| WO2011047204A1 (en) | Method of treating memory disorders and enhancing memory using igf-ii compounds | |
| KR20230113494A (en) | ADP-ribose binding peptide having anti-tumor activity, and uses thereof | |
| EP3254685B1 (en) | Composition for treating inflammatory disease induced by hyper-immune response | |
| WO2007079558B1 (en) | Proline-rich peptides, pharmaceutical composition, use of one or more peptides and method of treatment | |
| US20160230171A1 (en) | Methods for inducing glucose uptake | |
| Kim et al. | Altered regulation of nitric oxide and natriuretic peptide system in cisplatin-induced nephropathy | |
| US20070105942A1 (en) | Supplemental dietary composition for turning on anabolic switches in muscle, stimulating and/or optimizing protein synthesis, and/or potently signaling muscle building and/or growth via molecular pathways | |
| JP6484839B2 (en) | Novel peptide and its use | |
| WO2012104462A1 (en) | Heptapeptides and the use thereof for controlling hypertension | |
| US20060166890A1 (en) | Non-t cell binding peptides and their uses | |
| ES2951171T3 (en) | New composition containing branched chain amino acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 11813346 Country of ref document: US |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2008548908 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007700096 Country of ref document: EP |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |